SBIR/STTR Research Award
Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive
Award amount
$2,985,949Program and phase
SBIR · Phase IIAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Sentien Biotechnologies, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- NDAYRDKCMBJ7
- Solicitation number
- PA13-088
- Topic code
- NIDDK
Research abstract
DESCRIPTION (provided by applicant): The goal of this Phase IIB SBIR application is to test the Sentien cellular bioreactor product (the Sentinel ) in a first-in-man study to assess safety and preliminary efficacy. Fifteen post-cardiac surgery patients that are diagnosed with acute kidney injury and indicated for dialysis will be enrolled and connected to the Sentinel containing one of three escalating doses of cells, n=5 per dose: 250M, 500M and 1000M. Primary endpoints involve measures of safety, and patient samples will be taken for analysis by Sentien to evaluate possible trends in efficacy. The project specific aims are: (1) conduct a single- center, open-label, dose escalation safety study of the Sentinel in cardiac surgery patients diagnosed with AKIand indicated for CVVH; (2) measure experimental urine biomarkers for preliminary monitoring of device efficacy; and (3) profile the inflammatory response pathway in paired testing of patient blood. The deliverables of this project will be (1) a recor
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Stem Cell Bioreactor for Cardiac Care
- Stem Cell Bioreactor for Cardiac Care
- Transforming Dialysis into a Controlled Drug Delivery System for Stem Cell Derive
- Blood Purification for Organ Failure
- Cellular Device for the Treatment of Acute Liver Failure
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
9 SBIR/STTR records share this UEI (2010–2016). Reported award amounts total $10,643,887. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense, National Science Foundation